LEADER 01613nam  2200433 a 450 
001 9910701107803321
005 20130319090704.0
035   $a(CKB)5470000002415974
035   $a(OCoLC)813832666
035   $a(EXLCZ)995470000002415974
100   $a20121022d2005      ua             0
101 0 $aeng
135   $aurbn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aKAP keys for physicians$b[electronic resource] $ebased on TIP 40, clinical guidelines for the use of buprenorphine in the treatment of opioid addiction
210  1$a[Rockville, MD?] :$cU.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment,$d[2005]
215   $a1 online resource (16 unnumbered pages)
225 1 $aDHHS publication ;$vno. (SMA) 05-4105
225 1 $aTIP ;$v40
300   $aTitle from title screen (viewed on Oct. 22, 2012).
300   $a"CSAT's Knowledge Application Program."
517   $aKAP keys for physicians 
606   $aBuprenorphine$xTherapeutic use
606   $aOpioid abuse$xTreatment
606   $aDrug addiction$xTreatment
606   $aSubstance abuse$xDiagnosis
615  0$aBuprenorphine$xTherapeutic use.
615  0$aOpioid abuse$xTreatment.
615  0$aDrug addiction$xTreatment.
615  0$aSubstance abuse$xDiagnosis.
712 02$aCenter for Substance Abuse Treatment (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910701107803321
996   $aKAP keys for physicians$93484807
997   $aUNINA